The Conversation (0)
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) is proud to announce the publication of a pivotal research article in the prestigious Journal of Cosmetic Dermatology .
About the Study
Radiopharm Theranostics (ASX:RAD) is a biopharmaceutical company that develops radiopharmaceutical products for diagnostic and therapeutic applications. With four licensed platform technologies – nanobody, peptide, small molecules and monoclonal antibodies (mAb), Radiopharm aims to commercialize its pipeline for possible licensing and distribution agreements seeking to develop for the diagnosis and treatment of certain cancers.
Radiopharm Theranostics represents a promising investment opportunity in the rapidly growing field of radiopharmaceuticals, leveraging its innovative technology platform and diverse clinical pipeline.
Radiopharm’s clinical stage development in the pipeline include:
- PD-L1 (non-small cell lung cancer indication) - currently in phase 1 in Australia;
- HER2 (breast/gastric cancer indication) - will begin phase 1 trials this year;
- Integrin VB6 (pancreatic cancer indication) - now in Phase I imaging in pancreatic cancer.
- Fatty Acid Synthase (brain METS indication) - preclinical has been completed and with IND approval for Phase IIb Imaging
Company Highlights
- Radiopharm Theranostics is focused on developing and commercializing radiopharmaceutical products and nuclear medicines for both therapeutic and diagnostic applications in precision oncology.
- Radiopharm has four licensed platform technologies – nanobody, peptide, small molecules and monoclonal antibodies (mAb) – with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development.
- The company has received clearance from the US Food and Drug Administration for an investigational new drug application with two INDs (one for RAD 301 and one for RAD 101). Phase 1 for RAD 301 and for RAD 204 is in progress.
- The company aims to commercialize its pipeline for possible licensing and distribution agreements and has secured four platform technologies, which it is seeking to develop for the diagnosis and treatment of certain cancers.
This Radiopharm Theranostics profile is part of a paid investor education campaign.*
Click here to connect with Radiopharm Theranostics (ASX:RAD) to receive an Investor Presentation
RAD:AU
Radiopharm Theranostics Investor Kit
- Corporate info
- Insights
- Growth strategies
- Upcoming projects
GET YOUR FREE INVESTOR KIT
Radiopharm Theranostics
Investor Insight
Radiopharm Theranostics represents a promising investment opportunity in the rapidly growing field of radiopharmaceuticals, leveraging its innovative technology platform and diverse clinical pipeline.
Overview
Radiopharm Theranostics (ASX:RAD) is an innovative biopharmaceutical company specializing in the development of radiopharmaceutical products for both diagnostic and therapeutic applications. Founded with a mission to address significant unmet medical needs, particularly in oncology, the company has positioned itself at the forefront of the rapidly evolving field of precision medicine.
Radiopharm Theranostics presents a compelling value proposition for investors, characterized by several key factors:
- Strategic Partnerships
- Lantheus’ strategic investment in Radiopharm Theranostics, committing up to AU$18 million, strengthens Radiopharm's financial position and supports the advancement of its projects.
- Radiopharm owns 75 percent interest in Radiopharm Ventures, a joint venture created with The University of Texas MD Anderson Cancer Center, to develop novel radiopharmaceutical products for cancer treatment.
- Market Positioning: Radiopharm is strategically positioned to capture a significant share of the expanding theranostics market.
- Diverse Product Pipeline: The company boasts a robust pipeline of radiopharmaceutical products targeting various oncological diseases, which diversifies risk and increases potential revenue streams.
- Innovative Technology: Radiopharm's focus on leveraging technological advancements in radiopharmaceuticals, particularly in treating oncological diseases, positions it at the cutting edge of medical innovation.
Lantheus’ investment in Radiopharm marks a pivotal moment for both companies and holds substantial implications for the field of theranostics. The funding will facilitate Radiopharm's research and development efforts, accelerating its product pipeline and market presence. Under the agreement, Radiopharm will transfer two early preclinical assets to Lantheus for a further AU$3 million, fostering a collaborative relationship focused on radiopharmaceutical development. The collaboration positions Radiopharm to capitalize on the increasing demand for theranostic solutions, aligning with trends in personalized medicine. Moreover, this financial backing will support clinical trials and operational needs, while also aiming for the commercialization of their products.
Company Highlights
- Radiopharm Theranostics is focused on developing and commercializing radiopharmaceutical products and nuclear medicines for both therapeutic and diagnostic applications in precision oncology.
- Radiopharm has four licensed platform technologies – nanobody, peptide, small molecules and monoclonal antibodies (mAb) – with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development.
- The company has received clearance from the US Food and Drug Administration for an investigational new drug application with two INDs (one for RAD 301 and one for RAD 101). Phase 1 for RAD 301 and for RAD 204 is in progress.
- The company aims to commercialize its pipeline for possible licensing and distribution agreements and has secured four platform technologies, which it is seeking to develop for the diagnosis and treatment of certain cancers.
- Radiopharm owns 75 percent interest in Radiopharm Ventures, a joint venture created with The University of Texas MD Anderson Cancer Center.
Technology and Clinical Pipeline
Radiopharm has four licensed platform technologies – nanobody, peptide, small molecules and monoclonal antibodies (mAb) – with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development.
Radiopharm’s clinical stage development in the pipeline include:
- PD-L1 (non-small cell lung cancer indication) - currently in phase 1 in Australia;
- HER2 (breast/gastric cancer indication) - will begin phase 1 trials this year;
- Integrin VB6 (pancreatic cancer indication) - now in Phase I imaging in pancreatic cancer.
- Fatty Acid Synthase (brain METS indication) - preclinical has been completed and with IND approval for Phase IIb Imaging
The company recently received FDA approval for its investigational new drug application for 18-Pivalate (RAD 101). Labelled with the radioisotope F18, Pivalate is a small molecule that targets fatty acids synthase, which is overexpressed in brain tumours but not in normal cells.
Positive data from the company’s Phase 2 imaging trial of 17 patients with brain metastases has shown significant tumour uptake. Radiopharm holds an exclusive global license for the Pivalate platform.
Radiopharm highlights that Pivalate is potentially a new target for radiopharmaceutical brain imaging agents, and its unique mechanism of action may offer eligible patients a better option in relation to current imaging technology, which has many limitations.
Management Team
Paul Hopper – Executive Chairman
Paul Hopper is the founder of Radiopharm Theranostics. He has over 25 years of experience in the biotech, healthcare and life sciences. Focused on start-up and rapid-growth companies, he has served as the founder, chairman, non-executive director or CEO of more than 15 companies in the US, Australia and Asia. Previous and current boards include Imugene, Chimeric Therapeutics, Viralytics, Prescient Therapeutics and Polynoma. His experience covers extensive fund raising in US, Australia, Asia and Europe, and he has deep experience in corporate governance, risk management, and strategy.
Riccardo Canevari – Managing Director and Chief Executive Officer
Riccardo Canevari has broad and deep experience across specialty pharma, oncology and radiopharmaceuticals. He was most recently chief commercial officer of Novartis Advanced Accelerator Applications, one of the leading radiopharmaceutical and nuclear medicine companies, globally. He was responsible for global commercial strategy and country organizations in ~20 countries across North America, Europe and Asia. He was responsible for Lutathera’s in-market growth strategy and execution to build a blockbuster asset and for the pre-launch plan for Lu-PSMA 617 in metastatic prostate cancer. Prior to this, Canevari was senior vice-president and global head, breast cancer franchise for Novartis Oncology since 2017, overseeing the launch of major breast cancer products, including KISQALI and PIQRAY. He also held various management roles with Novartis Pharma and Ethicon/Johnson & Johnson.
Dr. Sherin Al-Safadi - Vice-president, Medical Affairs
Dr. Sherin Al-Safadi is an accomplished industry leader with many years of experience in pharmaceuticals and biotech. Most recently she was vice-president – medical affairs at POINT Biopharma, where she led the strategic and tactical planning for Phase III support and launch preparation of radiopharmaceuticals. She also provided strategic input and leadership for business development and licensing opportunities. She currently serves as co-founder and president at Foundation Amal (Canada-USA), overseeing an executive leadership team of 12 directors and members, who led the successful 2021 cross-border expansion into the USA and spearheaded the development of a successful branding and communication strategy. Al-Safadi holds a PhD in neurobiology from Concordia University, an MBA in entrepreneurship & management from the John Molson School of Business, and a MSc in pharmacology (oncology drug development) from McGill University.
Vimal Patel - Vice-president, CMC
Vimal Patel joins RAD from Orum Therapeutics where he was vice-president, head of CMC and supply chain. He was responsible for all CMC functions including process and analytical development, manufacturing, quality control, quality assurance, regulatory and supply chain. He led the successful manufacture of two ADCs and contributed to filing an IND leading to a Phase-I trial. Prior to Orum, Patel held roles of increasing responsibility in process development and manufacturing sciences at several companies, including Actinium Pharmaceuticals. Patel also held a position at Pfizer where he contributed to the refiling of Mylotarg and the filing of Besponsa BLAs. He also developed manufacturing processes for various ADCs. He also held roles at Daiichi Sankyo, Progenics Pharmaceuticals and SibTech in various capacities. Patel has MS in biotechnology from University of Connecticut and B.S. in chemical engineering from Sardar Patel University.
Noel Donnelly - Non-executive Director
Noel Donnelly brings more than 25 years of leadership experience in finance, strategy and operations within the biopharmaceutical and biotechnology industries. He has a distinguished track record of building and leading cross-functional teams, driving corporate governance and executing complex financial strategies that support rapid company. growth. Donnelly is current the chief financial officer of PepGen, where he oversaw the company's financial strategy through its successful IPO, raising U$120 million and leading subsequent financial efforts that secured an additional US$90 million. Donnelly was previously the CFO of EIP Pharma (now, CervoMed), where he led the company's IPO plannig phase. He had a 15-year tenure at Takeda/Shire PLC, in various senior roles, where he led critical R&D integrations and oversaw more than US$160 billion in integration planning and execution. He was instrumental in shaping the company's portfolio management strategy.
Radiopharm Theranostics ‘Extends Runway’ to Key Milestones with AU$70M Investments: Report
The anticipated acceleration in growth from the capital infusion and asset development synergy underscores the strategic significance of this partnership.
“This collaboration is pivotal, as Lantheus's expertise and established market presence in key regions, such as the US, Canada and Europe, significantly enhance the strategic value of their investment in Radiopharm,” the report said.
Under the agreement Lantheus will make an initial strategic equity investment of AU$7.5 million. Lantheus has an option to invest an additional AU$7.5 million within the next six months under the same terms. In addition, will transfer two early preclinical assets to Lantheus for AU$3 million. These assets include a TROP2 targeting nanobody and a LRRC15 targeting mAb.
“The anticipated acceleration in growth from the capital infusion and asset development synergy further underscores the strategic significance of this partnership.”
Highlights of the report:
- Strategic investment by and asset transfer agreement with Lantheus Holdings mark a significant enhancement in Radiopharm's growth strategy and capital strength
- Radiopharm has secured firm commitments from institutional and sophisticated investors for a significant capital increase through another placement totaling A$62.5 million.
- Radiopharm Theranostics is positioned in the growing radiopharmaceutical market, which is projected to reach $9.67 billion by 2026. The company's diversified portfolio targets various cancers, including prostate, breast, renal cell carcinoma, and lung cancer.
For the full analyst report, click here.
This content is intended only for persons who reside or access the website in jurisdictions with securities and other applicable laws which permit the distribution and consumption of this content and whose local law recognizes the scope and effect of this Disclaimer, its limitation of liability, and the legal effect of its exclusive jurisdiction and governing law provisions [link to Governing Law section of the Disclaimer page].
Any investment information contained on this website, including third party research reports, are provided strictly for informational purposes, are general in nature and not tailored for the specific needs of any person, and are not a solicitation or recommendation to purchase or sell a security or intended to provide investment advice. Readers are cautioned to seek the advice of a registered investment advisor regarding the appropriateness of investing in any securities or investment strategies mentioned on this website.
Sirona Biochem
Investor Insight
Sirona Biochem is on track to commercialize its proprietary anti-aging product, increasing shareholder value and enhancing profitability.
Overview
Sirona Biochem (TSXV:SBM,FSE:ZSB,US OTC:SRBCF) is a biotechnology company with an innovative platform for developing safer, more effective cosmetic and therapeutic active ingredients. Sirona Biochem’s strategy involves bringing innovative patented compounds to market while also engaging in partnerships to license or sell them to prominent global enterprises. In exchange, receiving income generating sales, front-end fees, milestone payments, and ongoing royalties.
Sirona’s technology is based on proprietary carbohydrate chemistry developed by the company’s wholly-owned French subsidiary research and development (R&D) laboratory TFChem. This carbohydrate chemistry can improve the safety and efficacy of carbohydrate-based molecules, which have broad application potential for the development of therapeutics and cosmeceuticals. Examples of commercially available carbohydrate-based drugs include viral neuraminidase inhibitor Tamiflu, and Johnson & Johnson’s (NYSE:JNJ) SGLT2 inhibitor Invokana™.
The company has an exclusive global licensing agreement with Allergan Aesthetics, an AbbVie company (NYSE:ABBV), to commercialize topical skin care treatments for dyschromia based on Sirona’s patents for TFC-1067 and related family of compounds. TFC-1067 is a very potent but safe dark spot remover and a breakthrough in the industry.
Sirona’s commercial launch of a serum containing our GlycoProteMim™ in 2025 is on track. The company’s Paris-based cosmetic branding expert has developed a compelling strategy to position this product as a premium offering in the anti-aging market highlighting GlycoProteMim's™ rejuvenating properties. GlycoProteMim™ serum will provide consumers with aging skin a breakthrough solution, delivering unmatched benefits without any observed adverse effects.
Sirona is led by a highly experienced team of biotechnology professionals. The company’s chief scientific officer Dr. Géraldine Deliencourt-Godefroy is an award-winning synthetic chemist and the founder of the French biotechnology company TFChem. Her scientific research in carbohydrate chemistry has led to the discovery of new drug families and the development of drug candidates for diabetes and obesity, cosmetic ingredients and biological adjuvants. She is the recipient of the acclaimed Francinov Research and Innovation Medal, the French Ministry of Research Award and the French Senate Award.
Technology Platform
Sirona’s technology platform is based on proprietary carbohydrate chemistry. Carbohydrate molecules play a central role in cell-to-cell communication and can interact with proteins, hormones, viruses, toxins and bacteria. In this way, carbohydrates perform a variety of essential biological functions in the human body, making them valuable components for the development of therapeutics and cosmeceuticals.
While they have broad application potential, carbohydrates are extremely challenging to develop due to their inherent instability. Using chemistry techniques originally developed by TFChem, Sirona has overcome the challenge of stabilizing carbohydrates to develop safer, more effective cosmetic and therapeutic active ingredients.
Sirona is exploring multiple commercial opportunities and partnerships for its carbohydrate technology platform and currently has two streams of product line: cosmetics and therapeutics.
Company Highlights
- Proven technology platform based on proprietary carbohydrate chemistry leading to a pipeline of products across a broad range of applications in cosmetics and pharmaceuticals all based on 20 years of research and development.
- Signed global exclusive licensing deal with Allergan Aesthetics, an AbbVie [NYSE: ABBV] company, for TFC-1067 and related family of compounds for the treatment of dyscromiadyschromia.
- Under the license agreement, Sirona will receive payments on achievement of milestones and royalties on product sales. Seventeen years duration for TFC-1067 patents.
- Strong worldwide IP portfolio, including North America, European Union and Asia.
- Developing disruptive solutions for anti-aging (US$12.5 billion), dyschromia(US$7.5 billion), and cellulite treatment (US$ 1.4 billion).
- Preparing for a planned commercial launch of anti-aging anti-wrinkle skincare product first quarter 2025 containing Sirona’s GlycoProteMim™ ingredient.
- State-of-the-art, laboratory in Paris France with award winning scientific team.
Key Business Segments
TFC-1067
June 13 2022 Sirona announced it has entered into a global licensing agreement with Allergan Aesthetics, an AbbVie company (NYSE:ABBV), pursuant to which Allergan Aesthetics will develop and commercialize topical skin care treatments based Sirona’s TFC-1067 and related family of compounds. Work is underway to bring product(s) containing TFC-1067 to commercial sales. Sirona will receive payments on the achievement of milestones and royalties on product sales.
GlycoProteMim™
GlycoProteMim™ (TFC-1326) is a revolutionary compound that offers remarkable anti-aging results and stands out as a beacon of innovation and safety. Unlike traditional alternatives such as toxins, dermal fillers, and retinoids, GlycoProteMim™ offers a unique solution that is safe and effective in reversing skin aging.
GlycoProteMim™ heightens cellular response to reactive oxygen species (ROS) and boosts SOD2. The compound also enhances hyaluronic acid synthesis and increases fibroblast proliferation, fortifying the collagen network.
Product Highlights:
- Safe for All Skin Types: GlycoProteMim™ is designed for all skin types. It has been proven to be tolerated by 100 percent of participants in clinical trials.
- Natural Progression, Not Injection: GlycoProteMim™ is a topical application and does not require invasive injections.
- Anti-Aging Efficacy: The product is loaded with powerful anti-inflammatory effects. It reverses aging and repairs skin, offering a comprehensive and permanent solution.
Multifaceted Benefits: GlycoProteMim™ outshines alternatives by helping improve skin laxity and quality and providing UV protection while enhancing the skin barrier. Retinoids, while effective, come with challenges like skin irritation and a lengthy onset period, making GlycoProteMim™ a more versatile and user-friendly alternative.
Sirona’s subsidiary, TFChem, has successfully received formulations for its eagerly awaited GlycoProteMim™ based anti-aging serum from its formulation partner, Global Beauty Consulting. The formulation intends to define the brand and lay the foundation for a broader range of products. This formulation will undergo standard safety evaluations and be used in the upcoming clinical trial. Sirona plans to launch the product in early 2025, ensuring compliance with regulatory standards in the European, US, and Canadian markets.
Cellulite Treatment, Wound care, and Keloid Treatments
Sirona’s scientists have identified new molecules underscoring its commitment to comprehensive skincare solutions developed by TFChem for the treatments of cellulite, wound care and keloids. Research plans have been developed and will be implemented when sufficient resources become available. There is a massive unmet need for effective treatments in these areas spanning both cosmetics and therapeutic markets.
Melasma Therapeutics
Sirona has retained the rights to commercialize TFC-1067 and related compound TFC-1394 as a therapeutic for the treatment of melasma. The potential exists to produce an effective therapeutic agent free of hydroquinone.
Management Team
Dr. Howard J. Verrico - CEO and Chairman of the Board
Dr. Verrico obtained his medical degree from the University of Toronto in 1985 and has been a member of the College of Physicians and Surgeons of British Columbia since July 1986. Dr. Verrico has extensive experience as a venture capitalist in the junior capital markets. He has acted as a venture capitalist for over 30 years, funding numerous start-ups and early-stage companies both in the private and public marketplace. He is the founder of Sirona Biochem building the company by investing his personal funds starting in 2006, He has accumulated his large share position through personal share purchases. He currently is solely focused on the success and growth of SIRONA Biochem as it enters a stage of rapid growth.
Géraldine Deliencourt-Godefroy - Chief Scientific Officer
Dr. Géraldine Deliencourt-Godefroy is an award-winning synthetic chemist and the founder of French-based biotechnology company TFChem. Since the acquisition of TFChem by Sirona Biochem in March 2011, Dr. Deliencourt-Godefroy has assumed the role of Chief Scientific Officer. Her scientific research in carbohydrate chemistry has led to the discovery of new drug families and the development of drug candidates for diabetes and obesity, cosmetic ingredients and biological adjuvants. Previous to founding TFChem, Dr. Deliencourt-Godefroy was a scientific leader at INSA (National Institute of Applied Sciences) in Rouen, France, where she developed a new technology on stabilized carbohydrates. Previous roles also include a post-doctoral position at the University College London and doctoral research at the Research Institute of Fine Organic Chemistry in Rouen, France. Dr. Deliencourt-Godefroy received a PhD and Masters in Organic Chemistry as well as her business degree from the University of France. She is the author of several publications and patents and is also the recipient of the acclaimed Francinov Research and Innovation Medal, the French Ministry of Research Award and the French Senate Award.
Christopher Hopton - Chief Financial Officer
Christopher Hopton brings 28 years of financial management and operations expertise to the company. His extensive background includes financial planning, accounting policy, and business process improvement. As a business investment and finance consultant, he has worked with multiple public and private companies. Noteworthy roles include serving as chief financial officer at Central Resources and Rio Silver, as well as a division controller at Canadian Airlines, where he managed a $200 million annual operating budget. He played a key role in the restructuring of 360 Networks, leading to its acquisition by Bell Canada. Hopton holds a Bachelor of Business Administration from Simon Fraser University and is a Certified Professional Accountant.
Sirona Biochem Announces Publication of Groundbreaking Study on TFC-1326 Compound in the Journal of Cosmetic Dermatology
The article, titled "TFC-1326 Compound Reduces Clinical Signs of Skin Aging: Evidence From In Vitro Human Adipose and Skin Models and Pilot Clinical Trial," highlights the groundbreaking efficacy of Sirona's proprietary compound TFC-1326 in reducing visible signs of skin aging.
Read the full article here:
Access the Study: TFC-1326 Compound Reduces Clinical Signs of Skin Aging. Evidence From In Vitro Human Adipose and Skin Models and Pilot Clinical Trial
The study, conducted by leading scientists at Diva Expertise in collaboration with Sirona Biochem, presents compelling data demonstrating the ability of TFC-1326 to target key mechanisms of skin aging.
Key Findings
Using advanced in vitro human adipose and skin models, as well as a pilot clinical trial, TFC-1326 was shown to:
- Enhance skin elasticity and firmness
- Stimulate the production of collagen and other extracellular matrix components
- Reduce the appearance of fine lines and wrinkles
Clinical Trial Results
The pilot clinical trial with a 1% TFC-1326 topical cream provided robust evidence supporting its safety and efficacy. Key results included:
- Visible improvement in skin texture, hydration, and overall appearance
These findings reinforce the compound's potential as a next-generation anti-aging solution.
Statements from Leadership
"Our innovative approach to carbohydrate chemistry has once again delivered transformative results," said Dr. Howard Verrico, CEO of Sirona Biochem. "The publication of these findings in the Journal of Cosmetic Dermatology is a testament to the cosmeceutical benefits of TFC-1326 on aged skin. We believe this compound has the capacity to redefine anti-aging skincare solutions."
"This marks a significant milestone for Sirona Biochem," added Dr. Verrico. "We are actively advancing discussions with potential commercial partners while also laying the groundwork to launch our own product, ensuring this groundbreaking technology reaches the market and delivers its full potential to consumers globally."
TFC-1326 and Trademark Information
TFC-1326 and its salt form, TFC-1325, are being marketed under the trademarked name GlycoProteMim .
Read the full study here:
TFC-1326 Compound Reduces Clinical Signs of Skin Aging. Evidence From In Vitro Human Adipose and Skin Models and Pilot Clinical Trial
About Diva Expertise
Diva Expertise is an innovative French biotech based in Toulouse, in the Biotechnologies Center of Pierre Potier, specializing in applied research on human adipose tissue.
With more than 15 years of expertise in physiology and physiopathology, Diva Expertise has established itself as a leader in human adipose tissue research. Their high-tech platform provides personalized research support, from cellular studies to human applications.
Adipose tissue, which composes the hypodermis (the third layer of the skin), plays a crucial role in skin homeostasis and serves as a key target for innovative anti-aging solutions.
For more information, visit: https://www.diva-expertise.com .
About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company focusing on innovative cosmetic and dermatology active ingredients with a proprietary platform technology.
Sirona specializes in stabilizing carbohydrate molecules to improve their efficacy and safety. Its patented compounds are licensed to leading companies worldwide, generating revenue through licensing fees, milestone payments, and royalties.
Sirona's laboratory, TFChem , is based in France and has received multiple French national scientific awards and grants from the European Union and French government.
For more information, visit: www.sironabiochem.com .
Contact Information
Investor Enquiries:
Christopher Hopton
Chief Financial Officer
(604) 641-4466
info@sironabiochem.com
Forward-Looking Statements
This news release includes certain statements that may be deemed "forward-looking statements". All statements in this new release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ
materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
News Provided by GlobeNewswire via QuoteMedia
AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT
Howard Chang , M.D., Ph.D., Joins as Senior Vice President of Research and Chief Scientific Officer
Amgen (NASDAQ:AMGN) today announced that Howard Chang M.D., Ph.D., will join the company as senior vice president of Research, effective Dec. 16, 2024 . Chang will also assume the title and responsibility of serving as Amgen's chief scientific officer, reporting to Jay Bradner M.D., executive vice president of Research and Development.
"Howard is one of our generation's foremost physician-scientists, with expertise in human genetics and a profound ability to distill complex disease biology into clarified targets," Bradner said. "Leading Research at Amgen is a vital role that shapes the disease-altering therapies we pursue for patients. Howard's high-technology approach to science, coupled with his groundbreaking research in gene control, cancer biology and stem cell biology, complements the work we do every day."
Chang will be responsible for establishing and leading all research priorities within Amgen's rare disease, oncology, inflammation and cardiometabolic therapeutic areas. He will also oversee operations in key research hubs from San Francisco to Thousand Oaks , and across the company's global network of specialized sites in Reykjavik , Copenhagen , Munich , British Columbia , and Maryland .
Chang succeeds the highly distinguished Ray Deshaies , Ph.D., former senior vice president of Research, whose departure was announced earlier this year.
About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2023, Amgen was named one of "America's Greatest Workplaces" by Newsweek, one of "America's Climate Leaders" by USA Today and one of the "World's Best Companies" by TIME.
For more information, visit Amgen.com and follow us on X (formerly known as Twitter), LinkedIn , Instagram , TikTok , YouTube and Threads .
Amgen Forward-Looking Statements
This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico , and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.
CONTACT: Amgen, Thousand Oaks
Madison Howard , 773-636-4910 (media)
Elissa Snook , 609-251-1407 (media)
Justin Claeys , 805-313-9775 (investors)
View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-announces-senior-executive-research-appointment-302312094.html
SOURCE Amgen
News Provided by PR Newswire via QuoteMedia
Radiopharm Theranostics Investor Kit
- Corporate info
- Insights
- Growth strategies
- Upcoming projects